...
首页> 外文期刊>Liver international : >Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis
【24h】

Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis

机译:Yttrium-90放射栓塞与索拉非尼治疗中度局部晚期肝细胞癌:倾向评分分析的队列研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background & AimsSorafenib and transarterial Y-90-radioembolization (TARE) are possible treatments for Barcelona Clinic Liver Cancer (BCLC) intermediate-advanced stage hepatocellular carcinoma (HCC). No study directly comparing sorafenib and TARE is currently available. This single-centre retrospective study compares the outcomes achieved with sorafenib and TARE in HCC patients potentially amenable to either therapy.
机译:背景与目的索拉非尼和经动脉Y-90放射栓塞(TARE)是巴塞罗那临床肝癌(BCLC)中晚期肝细胞癌(HCC)的可能治疗方法。目前尚无直接比较索拉非尼和TARE的研究。这项单中心回顾性研究比较了索拉非尼和TARE对可能接受这两种疗法的HCC患者的治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号